People

The People

Governance at Noritsu Koki grades a B+: a professional non-family CEO with real skin in the game (~$26M stake) runs a tightly-held holding company where the founding Nishimoto family (~47.5% combined) sets the tone, and a genuinely independent four-person outside board — including a CPA-chaired audit committee and a lawyer-chaired nominations committee — sits above them. The system is disciplined and shareholder-friendly where it matters (JMDC sale, buybacks, 3-for-1 split, rising stock comp). It loses half a letter grade because the CEO still sets individual director bonuses within the shareholder-approved cap, and one audit-committee independent has now crossed the 10-year tenure ceiling written into Noritsu's own independence standard.

The People Running This Company

Noritsu is a two-person executive operation that sits on top of three manufacturing subsidiaries. Everything turns on how much you trust the CEO/CFO duo and the non-executives who vet them.

Iwakiri is not a Nishimoto heir; he is a professional operator installed in 2018, aged 40 at the time, after the family's post-imaging diversification bets (healthcare, senior-lifestyle, agri) had produced more noise than value. Since then he has done the work: sold the JMDC minority to Omron for ¥110B at a full price, divested every non-manufacturing segment by 2024, re-concentrated around three high-share niches, and in the 2025 integrated report explicitly flagged that "the current niche strategy makes it difficult to respond to rapid changes," so expect more M&A. His 1.74% personal stake (~$26M at current price) is unusually large for a non-founder Japanese CEO and is the single strongest alignment signal on the page.

What They Get Paid

Executive pay is modest by global standards, heavily tilted to cash, and rising faster than headcount. FY2025 bumped the performance-linked bonus band from 20-40% of base to 50-80%, signalling that future upside pay — not base — is where the incentive now sits.

'role' is not a column in the dataset

The CEO's ~$1.3M package is a fraction of what a US small-cap CEO running a $1.5B market cap company would earn, but for a TSE Prime holding company with a controlling family it's fair. More important than the size: 30% of CEO pay is now restricted stock and performance-linked EBITDA stock options, and variable pay actually moves with results — FY2024 bonus paid at 129-187% of target because Operating EBITDA came in at ¥24.2B vs ¥18.8B target. The 2025 policy shift (bonus standard raised to 50-80% of base) pushes future pay further onto the performance side, which is the right direction. Outside directors earn an average of ~$42K each — low but appropriate for Japan and for Noritsu's complexity.

Are They Aligned?

This is the critical section. Alignment is genuinely strong on ownership and capital-return signals, mixed on compensation structure, and the one real watch item is the 42% controlling shareholder — which cuts both ways.

Ownership structure

The Nishimoto family — descendants of founder Kanichi Nishimoto, who died in 2005 — controls roughly 47.5% of the company through Nishimoto Kosan (41.88%) plus Kayo Nishimoto personally (5.59%). That is de-facto absolute control at any normal AGM. The family does not sit on the board, and the CEO is not a Nishimoto; governance is delegated to Iwakiri and the independent directors. For minority shareholders, the family's behavior since 2018 — supporting the disposal of the family-founded imaging business, the JMDC sale, a 3-for-1 split in July 2025, and ongoing buybacks — suggests the controlling holder is acting like a patient anchor rather than extracting value. There are no disclosed related-party transactions with the family.

Insider behavior and dilution

Capital allocation behavior

The behavior since 2022 reads shareholder-friendly: sold the JMDC minority at ~¥6,000 per share for ¥110B (well above the market price at announcement), used proceeds to clean the balance sheet (net cash ~¥64B) and start systematic returns, committed to a total-return-ratio ≥50% under MTMP FY30, and signed up to DOE of 3.5%+ through FY27 and 4.0%+ FY28-30. The February 2026 Senqcia acquisition is a new portfolio bet worth watching, but it does not appear to have reopened the pre-2018 "diworsification" era.

Skin-in-the-game score

8 / 10. Controlling family (47.5%) plus a non-family CEO who personally owns 1.74% (~$26M) is an unusually tight alignment configuration for TSE Prime. The company also holds 1.96% treasury stock. Points deducted for: the family vehicle is private and its internal governance is not public; the CEO sets his own individual bonus within the committee-vetted band; and there is no stock ownership guideline for directors beyond grants. No insider has sold in any way that suggests a negative view of fundamentals.

Board Quality

The board is small (6), majority independent (4), and actually diverse — 33% female, CPA-chaired audit, attorney-chaired nominations. The one real weakness is tenure: one audit-committee independent has just crossed Noritsu's own 10-year independence ceiling.

Strengths. Four of six seats are formally independent and each one has a concrete specialism: CPA (Ota), attorney (Takada), manufacturing and consumer marketing (Murase, ex-Bandai executive), environmental law (Machino). The Nomination & Remuneration committee is 3 independent directors plus 1 outside expert (zero management); the audit committee is 3 independent (zero management). Board attendance is disciplined — Iwakiri, Yokobari, Ota and Murase at 100%; Takada 13/14. The 2024 effectiveness evaluation was run by an anonymous third party, not by the CEO's staff.

Real weaknesses.

1. Audit-chair tenure. Akihisa Ota has been a Noritsu director since June 2015 — about 10 years 9 months. Noritsu's own independence standard caps non-executive tenure at 10 years. He remains classified as independent, but the seat should be refreshed at the next AGM.
2. Only one CEO-experienced independent. Only Iwakiri is a CEO by background; Murase's senior experience is as an executive officer at Bandai, not a CEO. A seasoned outside CEO would strengthen challenge during M&A decisions.
3. Manufacturing depth is thin at the parent board level. Murase brings some; most manufacturing knowledge sits in the subsidiary boards (Teibow, AlphaTheta, JLab), not at Noritsu Koki itself. Iwakiri has explicitly acknowledged this gap as the reason he recruited Murase.
4. CEO decides individual pay. Reasonable given company size but cleaner if the Nomination & Remuneration Committee had final authority rather than advisory.

What is not a concern: no anti-takeover poison pill, no cross-shareholdings of consequence (policy holdings were materially reduced via the JMDC sale), no related-party transactions with family or directors, no regulatory actions, no audit qualifications, and PwC Japan is the auditor.

The Verdict

Upgrade trigger: refresh the audit chair, and either add a seasoned manufacturing CEO as a second independent or transfer final bonus authority to the Nomination & Remuneration Committee. Either move pushes this to A-.

Downgrade trigger: a related-party transaction involving Nishimoto Kosan, a large acquisition with weak disclosure, or a pay-plan expansion that decouples from the current EBITDA / owners-attributable profit achievement formula.